OBJECTIVE: Interferon regulatory factor 5 (IRF-5) is a transcription factor that mediates intracellular signals activated by engagement of Toll-like receptors (TLRs). IRF5 polymorphisms are associated with an increased or decreased risk of systemic lupus erythematosus (SLE) in various human populations, but the precise role of IRF5 in SLE development is not fully understood. This study was undertaken to examine the role of IRF5 in the development of murine lupus. METHODS: We crossed gene-targeted IRF5-deficient (IRF5(-/-) ) mice with MRL/MpJ-lpr/lpr (MRL/lpr) mice and examined the progeny for survival, glomerulonephritis, autoantibody levels, immune system cell populations, and dendritic cell function. RESULTS: IRF5(-/-) MRL/lpr mice survived longer than control IRF5(+/+) MRL/lpr mice and displayed only very mild glomerulonephritis. Autoantibodies to SLE-related nuclear antigens were lower in IRF5(-/-) MRL/lpr mouse serum, and numbers of activated CD4+ T cells were reduced in the spleen. Splenic DCs from IRF5(-/-) MRL/lpr mice produced lower levels of inflammatory cytokines when treated in vitro with TLR-7 or TLR-9 ligands or immune complexes. Interferon-α production in response to CpG was also decreased. CONCLUSION: Our results show that IRF5 is a crucial driver of lupus development in mice, and indicate that IRF5 may be an attractive new target for therapeutic intervention to control disease in SLE patients.
OBJECTIVE:Interferon regulatory factor 5 (IRF-5) is a transcription factor that mediates intracellular signals activated by engagement of Toll-like receptors (TLRs). IRF5 polymorphisms are associated with an increased or decreased risk of systemic lupus erythematosus (SLE) in various human populations, but the precise role of IRF5 in SLE development is not fully understood. This study was undertaken to examine the role of IRF5 in the development of murine lupus. METHODS: We crossed gene-targeted IRF5-deficient (IRF5(-/-) ) mice with MRL/MpJ-lpr/lpr (MRL/lpr) mice and examined the progeny for survival, glomerulonephritis, autoantibody levels, immune system cell populations, and dendritic cell function. RESULTS:IRF5(-/-) MRL/lprmice survived longer than control IRF5(+/+) MRL/lprmice and displayed only very mild glomerulonephritis. Autoantibodies to SLE-related nuclear antigens were lower in IRF5(-/-) MRL/lprmouse serum, and numbers of activated CD4+ T cells were reduced in the spleen. Splenic DCs from IRF5(-/-) MRL/lprmice produced lower levels of inflammatory cytokines when treated in vitro with TLR-7 or TLR-9 ligands or immune complexes. Interferon-α production in response to CpG was also decreased. CONCLUSION: Our results show that IRF5 is a crucial driver of lupus development in mice, and indicate that IRF5 may be an attractive new target for therapeutic intervention to control disease in SLEpatients.
Authors: Shruti Sharma; Allison M Campbell; Jennie Chan; Stefan A Schattgen; Gregory M Orlowski; Ribhu Nayar; Annie H Huyler; Kerstin Nündel; Chandra Mohan; Leslie J Berg; Mark J Shlomchik; Ann Marshak-Rothstein; Katherine A Fitzgerald Journal: Proc Natl Acad Sci U S A Date: 2015-02-02 Impact factor: 11.205
Authors: Kei Yasuda; Kerstin Nündel; Amanda A Watkins; Tania Dhawan; Ramon G Bonegio; Jessalyn M Ubellacker; Ann Marshak-Rothstein; Ian R Rifkin Journal: Int Immunol Date: 2013-01-04 Impact factor: 4.823
Authors: K Santana-de Anda; D Gómez-Martín; A E Monsivais-Urenda; M Salgado-Bustamante; R González-Amaro; J Alcocer-Varela Journal: Clin Exp Immunol Date: 2014-12 Impact factor: 4.330
Authors: Amanda A Watkins; Kei Yasuda; Gabriella E Wilson; Tamar Aprahamian; Yao Xie; Elena Maganto-Garcia; Prachi Shukla; Lillian Oberlander; Bari Laskow; Hanni Menn-Josephy; Yuanyuan Wu; Pierre Duffau; Susan K Fried; Andrew H Lichtman; Ramon G Bonegio; Ian R Rifkin Journal: J Immunol Date: 2015-01-16 Impact factor: 5.422
Authors: Gabriel Courties; Timo Heidt; Matthew Sebas; Yoshiko Iwamoto; Derrick Jeon; Jessica Truelove; Benoit Tricot; Greg Wojtkiewicz; Partha Dutta; Hendrik B Sager; Anna Borodovsky; Tatiana Novobrantseva; Boris Klebanov; Kevin Fitzgerald; Daniel G Anderson; Peter Libby; Filip K Swirski; Ralph Weissleder; Matthias Nahrendorf Journal: J Am Coll Cardiol Date: 2013-12-18 Impact factor: 24.094